ArticlePreventive medicine reports2026
Glucagon-like peptide-1 receptor agonist use and risk of gynecologic cancers: a meta-analysis of multinational real-world cohort studies.
Article in Preventive medicine reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are widely used for the management of type 2 diabetes mellitus (T2DM) and obesity. Given the established links between metabolic dysfunction and gynecologic malignancies, the potential association between GLP-1RA use and gynecologic cancer risk remains clinically relevant but incompletely defined. We conducted a meta-analysis of real-world cohort studies to evaluate this association. Methods: We systematically searched PubMed (from 1966) and Embase (from 1974) through February 15, 2026 for observational cohort studies assessing the association between (GLP-1 RA) use and gynecologic cancer outcomes. Hazard ratios (HRs) with 95% confidence intervals (CIs) were pooled using random-effects models. Results: Nine retrospective cohort studies were included. GLP-1RA use was not significantly associated with gynecologic cancer risk (HR 0.80; 95% CI: 0.63, 1.01). In cancer subtype analyses, a reduced risk was observed for ovarian cancer (HR 0.68; 95% CI: 0.49, 0.93), whereas associations for endometrial, cervical, and other gynecologic cancers were not statistically significant. Conclusions: GLP-1RA use was not significantly associated with overall gynecologic cancer risk, although potential reductions were observed in obesity populations and for ovarian cancer. Given substantial heterogeneity and the observational nature of the evidence, these findings should be interpreted cautiously and considered hypothesis-generating.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.